Bruker (BRKR) Expected to Announce Earnings on Monday

Key Points

• Bruker is set to announce its Q2 2025 earnings on August 4th, with analysts expecting earnings of $0.43 per share and revenue of $811.17 million.
• The company recently paid a quarterly dividend of $0.05 per share, representing a 0.48% annualized yield.
• Insider trading is active, with CEO Frank H. Laukien recently purchasing 2,608 shares at an average cost of $38.36 per share.

Bruker (NASDAQ:BRKR - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $811.17 million for the quarter. Bruker has set its FY 2025 guidance at 2.400-2.480 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. The firm had revenue of $801.40 million for the quarter, compared to analysts' expectations of $763.83 million. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The business's quarterly revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.53 EPS. On average, analysts expect Bruker to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Bruker Trading Down 3.9%

NASDAQ BRKR traded down $1.59 during trading on Thursday, hitting $39.32. The stock had a trading volume of 1,203,550 shares, compared to its average volume of 2,321,473. The stock has a market capitalization of $5.96 billion, a price-to-earnings ratio of 75.86, a P/E/G ratio of 2.83 and a beta of 1.18. The stock has a 50 day simple moving average of $39.85 and a 200 day simple moving average of $43.89. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.74 and a current ratio of 1.57. Bruker has a one year low of $34.10 and a one year high of $72.94.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date of this dividend was Monday, June 16th. Bruker's dividend payout ratio (DPR) is 38.46%.

Analyst Ratings Changes

Several analysts recently issued reports on BRKR shares. Stifel Nicolaus dropped their price objective on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Bank of America dropped their target price on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Barclays decreased their target price on Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Citigroup lowered Bruker from a "strong-buy" rating to a "hold" rating and dropped their target price for the company from $50.00 to $40.00 in a research note on Thursday, May 22nd. Finally, Wells Fargo & Company reduced their price target on Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a report on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Bruker presently has a consensus rating of "Hold" and an average price target of $52.89.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien purchased 2,608 shares of the company's stock in a transaction that occurred on Friday, June 6th. The shares were bought at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the purchase, the chief executive officer owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This represents a 0.01% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 27.30% of the company's stock.

Institutional Investors Weigh In On Bruker

Large investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. purchased a new position in shares of Bruker during the first quarter valued at approximately $262,000. Focus Partners Wealth boosted its position in shares of Bruker by 115.0% during the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company's stock worth $469,000 after acquiring an additional 6,008 shares during the last quarter. Royal Bank of Canada raised its stake in Bruker by 8.3% during the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock valued at $5,148,000 after purchasing an additional 9,501 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Bruker by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company's stock valued at $15,285,000 after acquiring an additional 9,235 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock valued at $61,162,000 after acquiring an additional 758,301 shares during the period. Institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.